
|Articles|June 1, 2001
Bexarotene safe treatment for early-stage CTCL
Washington - Bexarotene gel appears to be an effective and well-tolerated monotherapy when used as first-line treatment for early-stage cutaneous T-cell lymphoma, Madeleine Duvic, M.D., reported at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
3
Top 5 Articles of the Week: December 7-12
4
Dermatology Times Spot Test: December 14, 2025
5


















